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ABSTRACT 
ROLE OF HDACS AND SAM IN INTERFERON-ALPHA SIGNALING AND 
EPIGENETIC REGULATION OF ANTI-HCV GENE EXPRESSION 
Stephanie A. Mathews 
November 28,2011 
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease in the 
United States and is a huge burden on the US healthcare system. The FDA-
approved traditional standard of care for HCV is pegylated interferon-alpha 
(lFNa) combined with ribavirin, which is effective in about 50% of patients. The 
molecular mechanisms involved in resistance to IFNa therapy remain unclear. 
Recent data strongly suggest that histone deacetylases (HDACs) and 
methylation play critical roles in the regulation of IFNa anti-HCV signaling and 
gene expression. The present work was carried out to elucidate the roles of 
HDACs and S-adenosylmethionine (SAM) metabolism in regulating IFNa anti-
HCV signaling in human hepatoma cells. 
Inhibition of HDACs, by pharmacologic HDAC inhibitors or siRNA, significantly 
suppressed IFNa-mediated antiviral gene expression and partially reversed the 
v 
anti-HCV action of IFNa in human hepatoma cells. The decrease in antiviral 
gene expression correlated with decreased retention time of activated STATs in 
the nucleus, an increase in STAT acetylation, inhibition of the STAT1 :HDAC1 
complex, and decreased occupancy of STAT1 on antiviral gene promoters. We 
used siRNA to specifically identify HDACs 1 and 3 as being critical for IFNa-
mediated anti-HCV activity. Finally, we showed that boosting HDAC gene 
expression by theophylline supplementation improved IFNa-mediated antiviral 
gene expression and anti-HCV activity, thus supporting the hypothesis that 
HDACs are critical for IFNa anti-HCV signaling. 
Impaired SAM metabolism, as a result of increased intracellular S-
adenosylhomocysteine, markedly reduced IFNa-mediated antiviral gene 
expression and anti-HCV activity, which correlated with a decrease in STAT 
phosphorylation and an increase in association between STAT1 and its negative 
regulator PIAS 1. We also showed that impaired SAM metabolism downregulated 
expression of several HDACs, which may also impact IFNa antiviral signaling. 
Importantly, SAM supplementation restored the antiviral and anti-HCV properties 
of IFNa. 
Acrolein, an environmental pollutant, significantly inhibited antiviral gene 
expression, which correlated to impaired STAT phosphorylation, decreased 
induction of class I HDAC mRNAs, and reduced HDAC activity in human 
hepatoma cells. The results presented herein reveal a critical role for HDACs 
VI 
and SAM metabolism in IFNa-mediated anti-HCV activity and support the use of 
SAM and/or inducers of HDACs as adjunct therapy in managing HCV infection. 
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Hepatitis C Virus 
CHAPTER I 
INTRODUCTION 
Hepatitis C virus (HCV) infection is a major cause of acute hepatitis and chronic 
liver disease in the United States (US) and is known to be a precursor to 
cirrhosis, end-stage liver disease, hepatocellular carcinoma (HCC) and death. It 
is estimated that more than 170 million persons worldwide are chronically 
infected with HCV and approximately 3 million of those live in the US5, 66, 68,104. 
The most recent statistics from the Centers for Disease Control and Prevention 
suggest that 55-85% of HCV infected subjects will develop chronic infections. 
Additionally, HCV remains one of the leading causes of liver transplantation in 
the US and is a huge burden on the US healthcare system; it is estimated that 
annual total medical costs for HCV patients will exceed $80 billion over the next 
15 years51 , 122. 
HCV is an enveloped, single-stranded RNA virus of the family Flaviviridae. The 
HCV genome is comprised of a single open reading frame (ORF) that is flanked 
1 
by 5' and 3' non-coding regions (NCR). The ORF encodes a polyprotein that is 
cleaved, both co- and post-translationally, to give rise to HCV core and envelope 
proteins as well as several nonstructural (NS) proteins. The NS5B protein 
functions as an RNA dependent RNA polymerase while other NS proteins 
function as proteases necessary for processing of the polyprotein 17,55,68. 
Importantly, the NS5A protein contains the interferon sensitivity determining 
region (ISDR), which is highly susceptible to mutations and is thought to 
determine early response to IFNa therapl1, 96,101,103. The 5' NCR contains an 
internal ribosomal entry site (IRES) and the 3' NCR contains elements that are 
required for efficient viral replication. The HCV genome has a great propensity 
for mutations, thereby producing many HCV variants, and this quality is thought 
to be related to its ability to induce chronic infection 17,72,119. This high mutation 
rate may also make it difficult to develop vaccines against HCV. 
HCV infection leads to the release of endogenous cytokines that invoke immune 
and inflammatory responses to aid in viral clearance. Of particular importance is 
induction of interferon alpha (IFNa), which activates the JAKISTAT signaling 
pathway, ultimately leading to expression of IFNa-stimulated antiviral genes. 
However, the virus also induces several countermeasures that inhibit the antiviral 
activity of IFNa including induction of protein phosphatase 2A (PP2A) and 
suppressor of cytokine signaling 1 and 3 (SOCS-1, SOCS-3), which interfere with 
JAKISTAT signaling 11,52,69,104. 
2 
Unfortunately, more than 75% of individuals infected with HCV show no signs or 
symptoms and the disease is usually not detected until it is in the chronic stage. 
Additionally, HCV infection can worsen underlying disease if it coexists with other 
hepatic conditions, such as alcoholic liver disease 122. There is no vaccine 
against HCV and the current FDA approved standard of care is pegylated-IFNa 
combined with ribavirin. Despite the antiviral properties of IFNa, up to 60% of 
patients fail to reach sustained virological response (SVR) particularly those 
infected with HCV genotype 1, which is most prevalent in the US. Response to 
IFNa therapy is dependent on several factors including viral load, obesity, alcohol 
consumption, smoking, and exposure to environmental pollutants35, 117, 122. In 
addition, the pegylated-IFNa/ribavirin treatment regimen is expensive and 
produces many harsh side effects. In 2011, two new protease inhibitors, 
boceprevir and telaprevir, were FDA-approved for treatment of HCV; however, 
they must be used in combination with pegylated-IFNa and ribavirin therapy and 
they are only effective against HCV genotype 1. Additionally, each of these 
protease inhibitors has a complicated dosing regimen, produces harsh side 
effects, and has numerous contraindications. Therefore, the need for enhancing 
the efficacy of the existing IFNa treatment is of critical importance. 
IFNa ANTIVIRAL SIGNALING and HeV 
IFNa is a ubiquitous cytokine with immunomodulatory and antiviral properties. 
IFNa is released from host cells and given as medication during HCV infection to 
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aid in clearance of the virus. The antiviral action of IFNa is mediated through 
binding with the cell surface receptors IFNAR1 and IFNAR2, which activates the 
JAKISTAT signaling pathway, ultimately leading to expression of IFNa-stimulated 
antiviral genes. Critical steps in this pathway include IFNa-mediated 
phosphorylation of the receptor-associated kinases Jak1 and Tyk2, which 
provides docking site for the inactive STAT proteins. Docking of STAT induces 
its phosphorylation on tyrosine residue 701 and serine residue 727. Once 
activated, the pSTAT proteins dissociate from the receptor and form STAT 
dimers that are translocated to the nucleus. Tyrosine phosphorylation of 
cytoplasmic STAT proteins is necessary for their dimerization and subsequent 
nuclear import while serine phosphorylation is required for optimal transcriptional 
activity. Once inside the nucleus, pSTATs associate with the transcription factor 
IRF-9 to form the interferon stimulated gene factor 3 (ISGF 3) transcription 
complex. ISGF3 binds the interferon stimulated response element (ISRE) within 
the promoter of IFNa stimulated genes and induces expression of several 
antiviral proteins including dsRNA-activated protein kinase (PKR) and 
oligoadenylate synthetases (OAS), which arrest viral protein synthesis and 
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Figure 1: Schematic of IFHa-stimulated JAKISTAT signaling. Modified from 
http://www.springerimages.com/lmages/MedicineAndPub/icHealthl1-
10.1007 s11154-008-9089-x-1 
Negative regulation of JAKS/STAT signaling occurs via several mechanisms. 
Nuclear pSTATs can be deactivated by phosphatases, which inhibits IFNa-
mediated transcription. Additionally, STAT forms a complex with the histone 
acetyltransferase (HAT) protein, esp, inside the nucleus, thus causing 
acetylation of STAT, which subsequently leads to its nuclear export, and arrested 
transcription of IFNa-stimulated antiviral genes 58,61 ,62. IFNa-mediated antiviral 
gene activation is also inhibited by association of ST AT1 with protein inhibitor of 
activated STAT (PIAS1) inside the nucleus of cells 73, 120. Importantly, arginine 
methylation of STAT1 prevents the STAT1 :PIAS1 association, and STAT1 
5 
methylation is also required for optimal transcriptional activitl5, 120. Additionally, 
histone deacetylase (HDAC) activity, which recruits RNA polymerase to the 
promoter of IFNa stimulated genes, is required for antiviral gene expression99. 
HCV induces several countermeasures to inhibit the antiviral activity of IFNa 
including induction of protein phosphatase 2A (PP2A), SOCS-1, and SOCS-3, all 
of which interfere with JAKISTAT signaling 11,27,42,43,73. Specifically, SOCS-1 
and SOCS-3 interact with receptor associated JAK to block its kinase activity, 
thereby preventing STAT phosphorylation. PP2A interferes with the signaling 
cascade by inhibiting protein arginine methyltransferase (PRMT)-mediated 
methylation of STAT proteins, which allows for association between STAT1 and 
its negative regulator, PIAS1 11 , 27,107. HCV also induces oxidative stress that 
impacts HDAC activity84. These alterations in HDAC activity might also affect the 
anti-HCV action of IFNa as HDACs are required to recruit RNA polymerase to the 
promoters of IFNa-stimulated genes86,99. 
S-adenosylmethionine and HCV 
S-adenosylmethionine (SAM) is of pivotal importance in cellular metabolism, 
serving as the major donor of methyl groups in transmethylation and 
transsulfuration reactions6, 14, 18,76. The majority of SAM synthesis occurs in the 
liver, whereby the adenosyl group from ATP is transferred to the sulfur atom in 
6 
methionine, in a reaction catalyzed by methionine adenosyltransferase (MAT). 
Once formed, SAM is rapidly metabolized to S-adenosylhomocysteine (SAH) by 
specific methyltransferases (MT) that transfer the methyl group from SAM to 
various molecules, including nucleic acids, proteins, and phospholipids. SAH 
hydrolase (SAHH) hydrolyzes SAH to yield adenosine and homocysteine, which 
is then converted back to methionine in a series of reactions catalyzed by 
homocysteine methyltransferase6, 14,47,80. The reaction catalyzed by SAHH is 
the only reversible reaction in the SAM metabolism pathway and the equilibrium 
favors the formation of SAH, however, the rapid uptake of adenosine and 
homocysteine by the cell drives the reaction in the direction of catalysis. 
Importantly, SAH is a potent inhibitor of cellular MTs, thus any increase in 
intracellular SAH levels will have detrimental effects on several transmethylation 
reactions. Methylation is essential for synthesis of several cellular components, 
including DNA and proteins, thus, intracellular SAM levels are critical for normal 
cell development and function. The ratio between SAM and SAH, called the 
methylation potential (MP), must be controlled for normal cellular function. 
Increases in intracellular SAH will decrease MP and block critical methylation 
reactions leading to abnormal cellular function6, 14,47,80. Several studies have 
shown that MAT1A mRNA levels are markedly reduced in patients with chronic 
liver disease, liver cirrhosis, or HCc5, 75. Importantly, elevated serum levels of 
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Figure 2: SAM metabolism schematic. 
~DZA. 
r--AD 
In cell culture systems, SAM metabolism can be disrupted by several 
mechanisms that raise intracellular SAH levels, thereby decreasing the 
SAM/SAH ratio and methylation potential. Targeting SAHH with pharmacologic 
inhibitors is an indirect mechanism to impair SAM metabolism. In 1977, Chiang 
et al. first reported the use of 3'-deazaadeonsine (DZA), a nucleoside analog of 
adenosine, as a potent inhibitor of SAHH that raised intracellular SAH and 
decreased SAM/SAH. Over the years, several other nucleoside analogs have 
been discovered that inhibit SAHH, including adenosine dialdehyde (AD) 7, 19, 20. 
Both DZA and AD bind to and inhibit SAHH leading to an increase in intracellular 
SAH and a decrease in methylation potential. Pharmacologic SAHH inhibitors 
8 
are a valuable tool for studying the effects of impaired SAM metabolism but 
inhibition of SAHH is only one mechanism that increases intracellular SAH. 
Since the products of SAH hydrolysis are adenosine and homocysteine and the 
equilibrium of the reversible SAHH reaction lies in the direction of SAH synthesis, 
administration of exogenous adenosine and homocysteine will also impair SAM 
metabolism by increasing intracellular SAH levels47 . 
Acrolein and HeV 
HCV disease progression and response to IFNa therapy depend on a variety of 
factors including obesity, oxidative stress, and external factors such as smoking, 
alcohol consumption, and exposure to environmental pollutants35, 117, 122. 
Acrolein is a highly reactive a,~-unsaturated aldehyde that humans are exposed 
to in a variety of situations. Importantly, acrolein is found in all sources of smoke 
including cigarette smoke, car exhaust, overheated cooking oils, and smoke from 
burning wood. Acrolein is also formed endogenously as a product of lipid 
peroxidation, a process that is also stimulated by acrolein, and is associated with 
oxidative stress54, 56, 65, 90. Recent studies also suggest that acrolein alters HDAC 
activit;. HDAC activity is required to recruit RNA polymerase to the promoters 
of IFNa-stimulated antiviral genes and is critical for efficient transcription of these 
genes. Accordingly, it is reasonable to speculate that exposure to acrolein may 
contribute to poor response to anti-HCV therapy. 
9 
Epigenetics 
A growing body of evidence suggests that DNA methylation and post-
translational histone modifications are important changes that will impact disease 
progression by inducing alterations in gene transcription, chromatin configuration, 
and DNA integriti' 41, 60, 86,111. Generally, CpG island methylation, which is 
mediated by DNA methyltransferases (DNMTs), results in transcriptional 
repression due to recruitment of methyl-CpG binding proteins, HDACs, and 
chromatin remodeling complexes 1. The modifications of lysine (K) residues on 
histone tails are indeed more complex. Histones associate with DNA to form 
nucleosomes, the fundamental repeating unit of eukaryotic chromatin. 
Specifically, 2 copies of each of the core histone proteins (H2A, H2B, H3, and 
H4) come together to form a histone octomer, which wraps 147 basepairs of 
DNA, thus forming a nucleosome. Nucleosomes function to package DNA into 
chromatin: euchromatin is loosely packaged and associated with active 
transcription, whereas heterochromatin is tightly packaged and associated with 
repressed transcription. Importantly, the modifications of the highly conserved 
histone tails are what facilitate DNA packaging 1,60, 111. The well-characterized 
modifications of histones occur on lysine (K) residues on the histone tails. In 
addition to methylation, it has been established that K residues are subject to 
modification by phosphorylation, acetylation, and ubiquitination. The most 
characterized modifications are methylation and acetylation, which are generally 
thought to repress and activate transcription, respectivell4, 111, 124. Importantly, 
these modifications are driven by various MTs, HDACs, and histone acetyl 
10 
transferases (HATs). It should be noted, however, that each K residue may be 
subject to more than one type of modification and these modifications may have 
different effects depending on the nature of local chromatin structure60, 64,111,124. 
DNA methylation and histone modifications work together to regulate gene 
transcription. In most cases, transcriptionally repressed genes are 
hypermethylated at CpG islands and associated with hypoacetylated histone H3 
that is methylated on the K9 residue (H3K9Me). Transcriptionally active genes 
are hypo methylated at CpG islands and associated with hyperacetylated and K4 
methylated H3 (H3K4Me)111, 124. Importantly, SAM functions as the major methyl 
donor during epigenetic modifications, so maintaining SAM and SAM/SAH levels 
are critical for methylation of DNA and histones. 
HDACs and HATs were historically named based on their ability to modify K 
residues on histone tails. HATs add negatively charged acetyl groups to K 
residues, which repel the negatively charged DNA, and are associated with 
loosely packed euchromatin and active transcription. HDACs remove the acetyl 
groups, which leads to attract of the histones to the DNA, and correlate with 
tightly packed heterochromatin and repressed transcription. 
11 
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Figure 3: Effect of HATs and HDACs on chromatin structure. Modified from 
http://missinglink.ucsf.edu/lm/genes_and_genomes/acetylation.html 
More recently, there has been an increasing body of evidence showing that 
HDACs and HATs, as well as MTs, also work on non-histone proteins 41, 87, 124. 
Importantly, HDACs have been implicated in the regulation of signaling by 
various transcription factors41 . IFNa-mediated antiviral gene expression relies on 
phosphorylation and nuclear import of STAT. Nuclear STAT proteins can be 
acetylated by CBP, a HAT protein, which marks STAT for nuclear export and 
leads to reduced antiviral gene transcription58, 62. In addition to being required to 
recruit RNA polymerase to IFNa-stimulated gene promoters, HDACs may playa 
role in IFNa anti-HCV gene expression by preventing STAT acetylation and 
increasing nuclear retention of activated STAT proteins. 
12 
Overall Hypothesis: 
The molecular mechanisms, which include both viral and host factors, involved in 
resistance to IFNa anti-HCV therapy are only beginning to be understood. A 
better understanding of these regulatory mechanisms may prove to be beneficial 
for enhancing the efficacy of IFNa. Recent data strongly suggest that HDACs 
and methylation playa critical role in regulation of IFNa signaling and antiviral 
gene expression. Importantly, HCV is known to modify HDAC activity and 
impaired SAM metabolism is a well-documented feature of chronic liver injury6, 77, 
84. Based on these findings, we hypothesized that HDACs and SAM play 
critical roles in regulating IFNa signaling and epigenetic regulation of anti-
HCV gene expression in hepatocytes. 
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CHAPTER II 
MATERIALS AND METHODS 
Cell Culture and Treatment: 
Huh7 cells (Apath, LLC, St. Louis, MO) were gown in Dulbecco's modified eagle 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 U/ml 
penicillin, 10 IJg/ml streptomycin, and 1x non-essential amino acids (NEAA). 
Huh7 cells stably transfected with an HCV replicon (HCVR) (clone B (S11791), 
Apath, LLC, St. Louis, MO) were grown in DMEM media supplemented with 10% 
FBS, 10 U/ml penicillin, 10 IJg/ml streptomycin, 1x NEAA, and 1mg/ml G418. 
Primary human hepatocytes were purchased from Zen-Bio (Research Triangle 
Park, NC) and maintained as per manufacturer's protocol. All cells were 
maintained in a 37°C and 5% C02 incubator. Cells were treated at a density of 
1.0 x 106 cells/ml in all experiments unless otherwise noted. For HDAC studies, 
cells were treated with the HDAC inhibitors tricostatin A (TSA, 400 ng/ml) or 
suberic bishydroxamate (SBHA, 10 IJg/ml) 30 minutes before stimulation with 
IFNa. Alternatively, cells were treated with the HDAC inducer, theophylline (1 
mM), for 24 hours prior to IFNa treatment. For SAM metabolism studies, cells 
were treated with the SAM metabolism disruptors, adenosine + homocysteine 
14 
(AdenHcy, 1 mM), adenosine dialdehyde (AD, 80 ~M), or 3-deazaadeonsine 
(DZA, 80 ~M) 3 hours prior to IFNa. For SAM supplementation studies, cells 
were treated for 24 hours with 1 mM SAM prior to IFNa treatment. To study the 
effects of SAM supplementation on impaired SAM metabolism, cells were treated 
with SAM metabolism inhibitors for 3 hours, then SAM for 24 hours, prior to 
stimulation with IFNa. For acrolein (ACR) studies, cells were treated with 25 or 
50 ~M ACR in serum-free DMEM for 30 minutes prior to IFNa treatment. 
Reagents and Antibodies: 
AD, DZA, adenosine, homocysteine, SAM, TSA, SBHA, ACR, theophylline and 
protease inhibitor cocktail were purchased from Sigma-Aldrich (St. louis, MO). 
Total STAT1and phospho-STAT1 (Tyr 701 and Ser 727) primary and goat anti-
rabbit horseradish peroxidase conjugated secondary antibodies were purchased 
from Cell Signaling (Danvers, MA). Anti-dimethyl arginine primary antibody was 
purchased from Abcam, Inc (Cambridge, MA). HCV NS5A antibody was a kind 
gift from Dr. Charles M. Rice (Rockefeller University). Protein AlG plus agarose 
was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Fetal 
bovine serum was purchased from Atlanta Biologicals (Norcross, GA). Tris-
buffered saline (TBS), DMEM, G418, NEAA, Trizol, and pre-stained protein 
ladder were purchased from Invitrogen (Carlsbad, CA). ECl western blotting 
detection reagent was purchased from Amersham Biosciences (Piscataway, NJ). 
Human IFNa was purchased from PBl Biomedical laboratories (Piscataway, 
NJ). Reagent for cDNA synthesis was purchased from Quanta BioSciences 
15 
(Gaithersburg, MD). SYBR Green RT-PCR reagent was purchased from Applied 
Biosystems (Foster City, CA). HCV PCR primer was purchased from Alpha DNA 
(Montreal, Canada). All other PCR primers were purchased from Integrated DNA 
Technologies (Coralville, IA). 
Western Blot: 
Cytoplasmic and nuclear protein extracts were prepared according to Dignam23. 
For whole cell Iysates, cells were washed twice with cold PBS and lysed with 
NETN buffer (150 mM NaCI, 1 mM EDTA, 20 mM Tris-HCI pH 8.0, 10% glycerol, 
0.5% Nonidet P-40, 1x protease inhibitor cocktail, sodium vanadate). Extraction 
buffers were supplemented with 1IJM TSAlml for acetylation studies. Proteins 
were separated by SDS-PAGE and transferred to PVDF membranes. 
Membranes were incubated in the appropriate primary antibodies overnight with 
gentle agitation at 4°C, washed with TBS-Tween, and incubated with the 
appropriate secondary antibodies for 1 hour. Proteins were visualized using ECl 
detection reagent as per the manufacturer's protocol. Pre-stained protein ladder 
was used to estimate the size of the transferred proteins. 
Immunoprecipitation: 
5 x 106 hepatoma cells were untreated or treated with SAM metabolism inhibitors 
for 3 hrs, HDAC inhibitors for 24 hours, and/or IFNa for 30 minutes. Following 
treatment, cells were washed 2 times with cold PBS and proteins were extracted 
as for western blot. Protein concentration was determined using Bio-Rad protein 
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assay per the manufacturer's protocol. Equivalent amounts of protein (250-500 
I-/g protein/sample) were adjusted to a volume of 500 1-/1 in PBS and incubated 
with immunoprecipitation antibody overnight with gentle agitation at 4°C. The 
following day, 20 1-/1 of protein AlG plus agarose beads was added for 3 hours 
with gentle agitation at 4°C. The immunoprecipitates were washed 4 times with 
PBS and the beads were subsequently resuspended in 40 1-/1 of 3x SOS-PAGE 
sample buffer, heated for 3 minutes at 95°C, briefly centrifuged, and 30 1-/1 of 
sample was separated by SOS-PAGE and subjected to the Western blotting 
procedure. 
RT-PCR: 
Real-time polymerase chain reaction (RT-PCR) assays were used to assess 2'5' 
OAS and PKR mRNA levels in Huh? cells and HCV RNA levels in HCVR cells. 
Total RNA was isolated from treated cells, after 2 hours (Huh?) or 24 hours 
(HCVR) of stimulation with IFNa, using TRlzol according to manufacturer's 
instructions. For real time PCR, the first strand cONA was synthesized using 200 
ng of total RNA and qScript cONA SuperMix (Quanta BioSciences) according to 
manufacturer's protocol. The RT conditions were 5 minutes at 25°C, 30 minutes 
at 42°C and 5 minutes at 85°C. Reactions in which the RNA was omitted served 
as negative controls. Real time PCR was performed with an ABI prism ?500 
sequence detection system using SYBR green I dye reagents. The specific 
primers were designed for human GAPOH, 2'5' OAS, PKR, ISG15, and HOACs 
17 
1-10, as well as HCV, using Primer3 software program. The following primers 
were used in real-time PCR: 
hGAPDH-RT -FP: 5' CTCTGCTCCTCCTGTTCGAC 3' 
hGAPDH-RT-RP: 5' TTAAAAGCAGCCCTGGTGAC 3' 
h 2'5'-OAS-RT-FP: 5' GCAGAAAGAGGGCGAGTTCT 3' 
h 2'5'-OAS-RT-RP: 5' CCTGGGCTGTGTTGAAATGT 3' 
hPKR-RT-FP: 5' CTTTGGCACCCAGATTTGAC 3' 
hPKR-RT -RP: 5' AAACTTGGCCAAA TCCACCT 3' 
hISG15-RT-FP: 5' CCCACAGCCATGGGCT 3' 
hISG15-RT-RP: 5' CGATCTTCTGGGTGATCTGC 3' 
hHDAC1-RT-FP: 5' CATCTCCTCAGCATTGGCTT 3' 
hHDAC1-RT-RP: 5' GACGGGGATGTTGGAAATTA 3' 
hHDAC2-RT-FP: 5' CAGCAAGTTATGGGTCATGC 3' 
hHDAC2-RT -RP:5' CCATGGCGTACAGTCAGGGA 3' 
hHDAC3-RT-FP: 5' GTTGTTCAGCTGGGTTGCTC 3' 
hHDAC3-RT-RP: 5' GAGAGTCAGCCCCACCAATA 3' 
hHDAC4-RT-FP: 5' AGGATTCAGCAGCTCCACTG 3' 
hHDAC4-RT -RP: 5' GAGCTCGTTGGAGCTATCGT 3' 
hHDAC5-RT-FP: 5' AGTGTGGGGTCCACAGAGC 3' 
hHDAC5-RT-RP: 5' ACTTCTCTGCACAGCATCCC 3' 
hHDAC6-RT -FP: 5' TCCAAGGCACA TTGATGGTA 3' 
hHDAC6-RT-RP: 5' CACAGTTCACCTTCGACCAG 3' 
hHDAC7-RT-FP: 5' CACTGGTGCTTCAGCATGAC 3' 
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hHDAC7-RT-RP: 5' GGCTCAGTCTTCCCCAGC 3' 
hHDAC8-RT-FP: 5' CCAGCACATAATCAGGACCA 3' 
hHDAC8-RT-RP: 5' ATTTTGGGAGGAGGAGGCTA 3' 
hHDAC9-RT-FP: 5' CCTCTCACGGACAACAGGGT 3' 
hHDAC9-RT-RP: 5' TGCACAGTATGATCAGCTCAG 3' 
hHDAC10-RT-FP: 5' GGCTGGAGTGGCTGCTATAC 3' 
hHDAC10-RT-RP: 5' CTGAGGGAGGAGACAGAAGC 3' 
HCV-RT-FP: 5' ATGGCGTTAGTATGAGTGTC 3' 
HCV-RT-RP: 5' GGCATTGAGCGGGTTGATC 3' 
The relative gene expression was analyzed using ZMCI method by normalizing 
with GAPDH gene expression in all experiments. 
Transfections: 
For siRNA transfections, Huh7 cells were plated in a 6-well plate at 0.3x1 06 
cells/well the day before transfection. On the day of transfection, cells were 
placed in serum- and additive-free DMEM prior to transfection. The siRNA 
transfection complex was prepared in sterile PBS using Fugene HD transfection 
reagent at the 3:2 (IJI Fugene: IJg DNA) ratio according to manufacturer's 
protocol and was allowed to incubate at room temperature for 15 minutes before 
dropwise addition to the appropriate wells, with swirling. After 6 hours, media 
was replaced with complete DMEM and transfection was continued for 48 hours 
(RNA) or 72 hours (protein) prior to stimulation with IFNa. After 48 hours, cells 
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that were transfected for protein extraction were trypsinized, transferred to new 
6-well plates, and allowed to incubate an additional 24 hours. For ISRE-
luciferase transfections, Huh? cells were plated at ?x1 06 cells in a T?5 flask the 
day before transfection. On the day of transfection, transfection complex was 
made by adding 18 1-11 of Fugene HD and 6 I-Ig ISRE-Iuciferase cis-reporting 
plasmid (Sratagene, La Jolla, CA) to 562 1-11 of serum-free DMEM containing 
pen/strep. Transfection complex was allowed to incubate at RT for 15 minutes 
before dropwise addition to the flask with swirling. The flask was incubated for 
24 hours and cells were then replated in a 24-well plate at 0.5x1 06 cells/well. 
Cells were allowed to adhere for 2 hours before treatment. 
Luciferase Reporter Assay: 
For cell lysis and detection of luciferase activity, a commercialluciferase assay 
kit (Promega, Madison, WI) was used according manufacturer's protocol. 
Luciferase activity was quantified in an Orion luminometer and normalized to 
protein concentration. 
Chromatin Immunoprecipitation (ChiP) Assay: 
Appropriately treated Huh? or HCVR cells were fixed with 1 % formaldehyde for 
10 minutes at RT. To stop fixation, 1.25M glycine was added to a final 
concentration of 0.125M in media and allowed to incubate for 5 minutes at RT. 
Media was removed from cells and cells were washed twice with PBS containing 
1x protease inhibitor cocktail (Sigma Aldrich) and 5mM sodium butyrate. 
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Following the wash, PBS was drained from the cells and chromatin was digested 
using the SimpleChlP Enzymatic Chromatin IP Kit (Cell Signaling, Danvers, MA) 
according to manufacturer's protocol. Chromatin concentration was measured 
as DNA using Nanodrop and digestion of chromatin was analyzed using 6% 
acrylamide gel. For immunoprecipitation, 20jJg of chromatin was diluted in ChiP 
dilution buffer and incubated with 10jJg STAT1 antibody and 20jJi protein A 
magnetic beads overnight at 4°C with rotation. The next day, the 
immunocomplexes were washed and crosslinking was reversed following 
manufacturer's protocol. After reversal of crosslin king, DNA was purified using 
the UltraClean DNA Purification Kit (MO BIO Laboratories, Carlsbad, CA) and 
subject to real-time PCR with specific primers for IRF-1 (SABiosciences, 
Frederick, MD). To determine changes in STAT1 occupancy at the IRF-1 
promoter, data were normalized to input and compared to UT cells. 
HDAC Activity Assay: 
The Epigenase HDAC Activity/Inhibition Direct Assay Kit (Epigentek, 
Farmingdale, NY) was used according to manufacturer's protocol to measure 
HDAC activity in nuclear Iysates. 
SAM and SAH Measurement by HPLC: 
Intracellular SAM and SAH levels were measured in deproteinized extracts as 
described previously (Song, Zhou et al. 2007). 
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Statistical Analysis: 
All data are presented as mean ± standard deviation of the mean (SDM). The 
method of analysis used was one-way analysis of variance (ANOVA) with the 
Tukey-Kramer multiple-comparison test. Differences were considered 




HISTONE DEACETYLASES AND INTERFERON-ALPHA SIGNALING 
Class I HDACs are required for IFHa-mediated antiviral signaling in human 
hepatoma cells. 
The anti-HCV action of IFNa is due, in part, to its activation of antiviral genes 
such as PKR, OAS, and ISG15. To examine the possible role of HDACs in 
regulation of IFNa-mediated anti-HCV gene expression, a human hepatoma cell 
line stably transfected with an HCV replicon (HCVR cells) was pretreated for 30 
minutes with two class I HDAC inhibitors (HDACi), TSA and SBHA, followed by 
stimulation with IFNa for 2 hours. Our data revealed that inhibition of class I 
HDACs significantly downregulated induction of the IFNa-stimulated antiviral 
genes. To confirm that this result was not an artifact of using a transfected cell 
line, we conducted the same experiment in the parental Huh? cell line. As seen 
with HCVR, pretreatment of Huh? cells with HDACi significantly inhibited IFNa-
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Figure 4: Class I HDACs are required for IFNa-mediated antiviral gene 
expression via the ISRE in human hepatoma cells. Human hepatoma cells 
treated for 2 hours with 1 OOUlmllFNa showed robust induction of the antiviral 
genes PKR, OAS, and ISG15, which was significantly reduced by pretreatment 
with TSA or SBHA. Pretreatment with TSA or SBHA also blocked IFNa-
stimulated ISRE activation. Error bars indicate SDM (N=3; a= P~ 0.05 vs UT, b= 
P~ 0.05 vs IFN). 
IFNa-mediated transcription of anti-HCV genes requires binding of the ISGF3 
transcription complex to the ISRE, a cis-acting DNA sequence that is common in 
antiviral gene promoters38, 42, 63, 100. To determine if HDACi-induced suppression 
of IFNa anti-HCV gene expression was due to impaired activation of the ISRE, 
we analyzed ISRE-driven luciferase activation in Huh? cells. Briefly, cells were 
transiently transfected with an ISRE-Iuciferase reporter plasmid and reseeded 
into 24-well plates prior to treatment with HDACi for 30 minutes and stimulation 
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with IFNa for 6 hours. Following stimulation, cells were lysed and equivalent 
amounts of Iysates were measured for luciferase activity. Treatment with IFNa 
alone caused robust activation of the ISRE, which was markedly inhibited by 
pretreatment with HDACi (Fig. 4). These data suggest that the suppression of 
IFNa stimulated antiviral genes caused by HDACi is partially due to impaired 
transcriptional activation of ISRE in the promoters of the genes. 
After evaluating the effects of HDACi on the host antiviral response, we were 
interested in the effect of HDAC inhibition on IFNa-mediated suppression of HCV 
RNA replication. Preliminary experiments revealed that 10U/mllFNa was 
sufficient to suppress HCV RNA induction by 50% after 24 hours of exposure. 
To determine how HDACs affect the anti-HCV action of IFNa, HCVR cells were 
pretreated for 30 minutes with HDACi prior to stimulation with 1 OU/mllFNa for 24 
hours. Interestingly, cells that were pretreated with HDACi showed significant 
inhibition of IFNa-mediated suppression of HCV (Fig. 5). Taken together, these 
results show that HDACi significantly inhibited expression of IFNa-stimulated 
anti-HCV genes, which correlated to impaired activation of the ISRE and an 
increase in HCV RNA induction. These data suggest a critical role for class I 
HDACs in the regulation of IFNa-mediated anti-HCV activity. Importantly, these 
data are comparable to data from other published reports that show a need for 
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Figure 5: Class I HDACs are required for IFNa-mediated anti-HCV activity. 
IFNa suppressed HCV RNA induction by 50% in HCVR cells, which was partially 
reversed by pretreatment with TSA or SBHA. Error bars indicate SDM (N=3; a= 
p~ 0.05 vs UT, b= p~ 0.05 vs IFN). 
Class I HDACs are required for IFNa-mediated antiviral signaling in primary 
human hepatocytes. 
Huh? cells are a well established model system for studying human hepatocytes 
but consideration must be given to the fact they are cultured hepatoma cells and 
may not exhibit the same response as primary human hepatocytes. To address 
this issue, we analyzed the effects of HDACi on IFNa-mediated antiviral gene 
expression in commercially available primary human hepatocytes. The primary 
hepatocytes were stimulated for 3 hours with 1 OOOU/mllFNa alone or after 
exposure to HDACi for 30 minutes. Total RNA was extracted and RT-PCR was 
used to analyze mRNA induction of the antiviral genes PKR, OAS, and ISG15. 
IFNa alone led to a 3- to 15-fold induction of all antiviral genes, which was 
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significantly inhibited by pretreatment with HDACi (Fig. 6). These results agree 
with our data from the hepatoma cell lines and confirm the requirement of class I 




























SBHA+IFN UT IFN TSA+IFN SBHA+IFN 
SBHA+IFN 
Figure 6: Class I HDACs are required for IFNa-mediated antiviral gene 
expression in primary human hepatocytes. Primary human hepatocytes 
treated for 3 hours with 1 OOOUlmllFNa showed robust induction of the antiviral 
genes PKR, OAS, and ISG15, which was significantly reduced by pretreatment 
with TSA or SBHA. Error bars indicate SDM (N=3; a= P~ 0.05 vs UT, b= p~ 0.05 
vs IFN). 
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Class I HDACs are required for retention of pSTAT1 in the nucleus of 
human hepatoma cells. 
The antiviral action of IFNa is mediated through activation of the JAKISTAT 
pathway. Critical steps in this pathway include the phosphorylation and nuclear 
import of STAT1. IFNa treatment leads to phosphorylation of STAT1 on Y701 
and S727, which is required for nuclear translocation and transcriptional activity, 
respectively38,100, 121,127. To determine if HDACs playa role in JAKISTAT 
signaling, human hepatoma cells were pretreated with HDACi for 30 minutes 
prior to stimulation with IFNa for various time pOints. Nuclear and cytoplasmic 
proteins were analyzed by Western blot for pSTAT1 protein expression. HDACi 
did not inhibit phosphorylation of STAT 1 , however, compared to cells stimulated 
with IFNa alone, there was an obvious difference in partitioning of pSTAT1. 
Expression of pSTAT1 (Y701 and S727) in cells exposed to only IFNa was 
mostly localized to the nucleus whereas pretreatment with HDACi led to 
cytoplasmic accumulation of pSTAT1. The partitioning of pSTAT1 was evident 
as early as 15 minutes after exposure to IFNa and could still be seen after 60 
minutes. Here, we show the partitioning 45 minutes after exposure to IFNa (Fig. 
7). Blots were also probed with total STAT1 and showed equal loading between 
samples except total STAT levels were markedly less in cytoplasmic Iysates that 
received IFNa. To ensure our result was not due to uneven loading of our 
protein samples, blots were probed with ~-actin or histone H3 to confirm equal 
loading in the cytoplasmic and nuclear extracts, respectively (Fig. 7, bottom 
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panel). These data reveal of role for HDACs in the nuclear retention of activated 












SBHA TSA SBHA 
+ + + 





Figure 7: Class I HDACs are required for retention of pSTAT1 in the 
nucleus of human hepatoma cells. Cytoplasmic (CE) and nuclear (NE) 
protein extracts were collected from Huh 7 cells stimulated with IFNa alone, or 
after pretreatment with TSA or SBHA, and analyzed by Western blot. 
Pretreatment with HDACi decreased retention of pSTAT1 in the nucleus, which 
correlated with accumulation of pSTAT1 in the cytoplasm, compared to cells 
stimulated with IFNa alone. {3-actin and histone H3 antibodies were used to 
confirm equal loading of proteins between cytoplasmic and nuclear samples, 
respectively. 
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Inhibition of HDACs decreases the association between HDAC1 and STAT1 
in the nucleus of human hepatoma cells and correlates with increased 
STAT1 acetylation. 
It has been established that STAT1 can be acetylated in the nucleus, due to 
binding with HATs such as CSP, which will lead to its translocation back out to 
the cytoplasm58,61,62. Since the acetylation status is due, in part, to a balance 
between the activities of HATs and HDACs, we determined: 1) STAT1 
interaction with HDACs in the nucleus; and 2) STAT1 acetylation status in 
response to inhibition of HDACs. Using nuclear extracts from Huh? cells treated 
with IFNa alone or after HDACi pretreatment, we performed 
immunoprecipitations with an antibody against ST AT1 and probed the nuclear 
STAT1 proteins by Western blot for association with HDACs. In cells stimulated 
with IFNa alone, there was a marked increase in association between STAT1 
and HDAC1, which was blocked by pretreatment with HDACi (Fig. 8, top). Next, 
we determined whether or not HDACi-induced dissociation of the IFNa-
stimulated STAT1 :HDAC1 complex correlated to an increase in acetylation of 
STAT1. Nuclear Iysates were immunoprecipitated with an acetylated-Iysine 
antibody and probed for STAT1 by Western blot. The impaired association 
between STAT1 and HDAC1, caused by HDACi pretreatment, correlated with an 
increase in STAT1 acetylation not seen in cells that only received IFNa (Fig. 8, 
bottom). These results suggest HDACs playa role in regulation of IFNa-
mediated antiviral gene expression by binding STAT proteins to keep them 
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Figure 8: Class I HDACs are required for IFNa-mediated STAT1 :HDAC1 
association and to prevent acetylation of STAT1 in the nucleus of human 
hepatoma cells. (Top) Pretreatment with SBHA inhibited IFNa-stimulated 
formation of STAT1:HDAC1 complex in the nucleus of Huh? cells. (Bottom) 
Pretreatment with SBHA enhanced acetylation of STAT1 and correlated with 
inhibition of the IFNa-stimulated STA T1 :HDAC1 complex. 
Class I HDACs are required for IFNa-mediated antiviral PKR and ISG15 
protein expression and suppression of viral NS5A protein expression. 
RT-PCR data showed that HDACi caused significant inhibition of IFNa-mediated 
host antiviral mRNA induction and suppression of HCV RNA, hence we wanted 
to verify that these results correlated to suppression of host antiviral proteins and 
viral proteins. We performed Western blots using whole cell Iysates from HCVR 
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cells that were stimulated for 24 hours with IFNa alone and after 30 minute 
pretreatment with HDACi. Using antibodies for the antiviral PKR and ISG15 
proteins and the viral NS5A protein, we found that HDACi blocked both IFNa-
stimulated antiviral protein expression and IFNa-mediated suppression of NS5A 
(Fig. 9). These results are consistent with our PCR data and further support the 
hypothesis that HDACs playa critical role in the anti-HCV actions of IFNa. 
SBHA 
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Figure 9: Class I HDACs are required for IFNa-mediated expression of the 
antiviral proteins PKR and ISG15 and suppression of viral NS5A protein in 
human hepatoma cells. Western blot analysis of whole cell Iysates from IFNa-
stimulated HCVR cells revealed an increase in antiviral PKR and ISG15 protein 
expression, which correlated with a decrease in viral NS5A protein expression. 
Pretreatment with SBHA inhibited IFNa-mediated antiviral protein expression and 
suppression of NS5A. f3-actin antibody was used to confirm equal loading of 
protein between samples. 
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Class I HDACs are required for association of STAT1 with the IRF-1 
promoter. 
The results presented thus far clearly show that class I HDACs play an important 
role in IFNa-stimulated activation of the JAKISTAT signaling cascade, host 
antiviral gene induction and protein expression, and IFNa-mediated suppression 
of HCV RNA and NS5A protein. Since HDACs also modify chromatin, we 
wanted to determine if inhibition of HDACs modified the epigenetic landscape at 
the promoter of the IFNa stimulated gene IRF-1 (interferon response factor 1). 
We performed chromatin immunoprecipitation (ChiP) analysis using an antibody 
for STAT1 and primers specific for the IRF-1 promoter. Briefly, appropriately 
treated HCVR cells were fixed with formaldehyde to crosslink proteins to DNA, 
nuclei were isolated and subjected to enzymatic digestion to cleave chromatin, 
and the digested chromatin was incubated with primary STAT1 antibody and 
magnetic beads. Following incubation, the immunocomplexes were washed, 
crosslin king was reversed, and DNA was purified prior to analysis by RT-PCR. 
As seen in Figure 10, HDACi pretreatment significantly decreased the 
association of STAT1 with the IRF-1 promoter. This result correlated with the 
significant downregulation of IFNa-stimulated antiviral genes seen previously as 
STAT1 is part of the ISGF3 transcription complex that must be bound to the 
promoter for active transcription of those genes. Taken together, our results 
show that class I HDACs are essential for IFNa-mediated activation of the 
JAKISTAT signaling cascade, association of transcription factors with the 
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Figure 10: Class I HDACs are required for association of STAT1 with the 
IRF-1 promoter in human hepatoma cel/s. Chromatin was isolated from 
HCVR cells stimulated with IFNa alone, or after pretreatment with TSA or SBHA, 
and STAT1 occupancy at the IRF-1 promoter was analyzed by ChiP assay. 
HDACi pretreatment decreased the IFNa-stimulated association of STAT1 with 
the IRF-1 promoter. Result is representative of 2 independent experiments. 
HDACs 1 and 3 are required for IFNa-mediated antiviral gene expression in 
human hepatocytes. 
Since the pharmacologic HDAC inhibitors SBHA and TSA block the activity of all 
class I HDACs, we used siRNA to determine if any or all of the class I HDACs 
were necessary for IFNa-mediated anti-HCV gene expression. Huh7 were plated 
at a density of 0.3 x 106 cells/well and transfected for 72 hours with siRNA 
specific for HDACs 1, 2, 3, or 8. Cells were transfected with a nonspecific 
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scramble siRNA to serve as a negative control. Following transfection , total 
RNA and protein extracts were collected and used to verify knockdown of the 
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Figure 11: Silencing ofHDACs in human hepatoma cells. Human hepatoma 
cells were transfected with siRNA specific for HDACs 1 and 3 for 72 hours (RNA) 
or 96 hours (protein), following the manufacturer's protocol. As negative 
controls, cells were either treated with transfection reagent alone (NT) or non-
specific scramble siRNA (scr). (Left) Real-time PCR showed specific knockdown 
of HDAC1 and HDAC3 mRNA induction by siHDAC1 and siHDAC3, respectively. 
Error bars indicate SDM (N=3; a= P~ 0.05 vs NT) . 
(Right) Western blot analysis of whole cell protein Iysates revealed that 
siHDAC1 and siHDAC3 specifically suppressed expression of HDAC1 and 
HDAC3 proteins, respectively. f3-actin antibody was used to verify equal loading 
between protein samples. 
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Once the specific knockdown of each HDAC was confirmed, the transfections 
were repeated and cells were stimulated with IFNa to determine the specific 
class I HDAC(s) that are critical for IFNa-mediated antiviral gene induction and 
protein expression. We found HDACs 1 and 3 to be critical for IFNa-mediated 
antiviral genes as silencing of those HDACs led to a partial, yet significant, 
decrease in IFNa-mediated induction of PKR, OAS, and ISG15 (Fig. 12). 
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Figure 12: HDAC1 and HDAC3 are required for IFHa-mediated antiviral 
gene expression in human hepatoma cells. Human hepatoma cells were 
transfected with siRNA specific for HOAC1 or HOAC3 for 72 hours prior to 
stimulation with 1 OOUlmllFNa for 2 hours. Nontransfected (NT) cells were 
treated with transfection reagent alone and served as the negative control. Real-
time peR analysis showed transfection with siHOAC1 or siHOAC3 caused 
partial, but significant, inhibition of IFNa-stimulated induction of PKR, OAS, and 
ISG15. Error bars indicate SOM (N=3; a= P~ 0.05 vs IFN). 
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After identifying HDACs 1 and 3 as being critical for IFNa-mediated antiviral gene 
induction, we wanted to determine if silencing of these HDACs affected the 
STAT1 : HDAC 1 association and/or expression of the antiviral protein, PKR. Using 
whole cell Iysates from siRNA transfected cells, we performed an 
immunoprecipitation using STAT1 antibody and looked for HDAC1 by western 
blot. As expected, cells that did not express HDAC1 did not show a 
STAT1 :HDAC1 association. Interestingly, silencing of HDAC3 also inhibited the 
STAT1 :HDAC1 association (Fig. 13). Finally, silencing of both HDAC 1 and 3 
decreased expression of the antiviral protein PKR (Fig. 13). These results 
support the previous data using pharmacologic class I HDAC inhibitors and 
specifically identify HDACs 1 and 3 as being critical for induction of IFNa-











Figure 13: HDAC1 and HDAC3 are required for IFHa-mediated PKR protein 
expression and IFHa-mediated STAT1:HDAC1 association in human 
hepatoma cells. Huh7 cells were transfected with siRNA specific for HDAC1 or 
HDAC3 for 96 hours prior to stimulation with 1000UlmllFNa for 1 hour. Non-
transfected (NT) cells received transfection reagent alone and served as 
negative control. (Top) Western blot analysis showed that siHDAC1 and 
siHDAC3 suppressed IFNa-stimulated PKR protein expression. f3-actin antibody 
was used to ensure equal loading of protein between samples. (Bottom) 
siHDAC1 and siHDAC3 inhibited IFNa-induced STAT1:HDAC1 complex 
formation in whole cell protein Iysates. 
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Theophylline boosts HDAC1 gene induction and improves IFNa-mediated 
anti-HCV gene induction and activity. 
After confirming the requirement for HDACs in the regulation of IFNa-mediated 
anti-HCV activity, we wanted to determine if boosting HDACs could improve the 
antiviral actions of IFNa. Recent reports implicate theophylline in boosting HDAC 
activity and modifying inducible signaling pathways22, 53, 128. To elucidate the role 
of theophylline in IFNa-mediated anti-HCV activity, HCVR cells were treated for 
48 hours with increasing doses of theophylline prior to stimulation with IFNa for 
24 hours. Total RNA was extracted and used to analyze PKR mRNA induction 
and HCV RNA by RT-PCR. As seen in Figure 14, theophylline boosted IFNa-
mediated PKR mRNA induction and enhanced its anti-HCV action. Importantly, 
theophylline alone induced PKR and HDAC1 mRNA and suppressed HCV. 
These data provide additional support to the hypothesis that HDACs are critical 
for the antiviral actions of IFNa and suggest a role for theophylline, or other 
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Figure 14: Theophylline enhances IFNa-mediated PKR mRNA induction and 
anti-HCVactivity and boosts HDAC1 mRNA induction in human hepatoma 
cells. Theophylline pretreatment enhanced IFNa-stimulated PKR mRNA 
induction and suppression of HCV RNA. Theophylline alone significantly induced 
PKR and HDAC1 mRNA induction and suppressed HCV RNA. Error bars 
indicate SDM (N=3; a= P~ 0.05 vs UT, b= P~ 0.05 vs IFN). 
40 
Summary of data: 
.:. Pharmacological inhibition of Class I HDACs showed that HDACs are 
required: 
o for IFNa-mediated antiviral gene expression and anti-HCV activity 
o for retention of pSTAT1 in the nucleus 
o for STAT1 :HDAC1 association in the nucleus 
o to prevent acetylation of ST AT1 
.:. Studies with siRNA identified HDACs 1 and 3 as being critical for IFNa-
mediated antiviral activity . 
• :. Theophylline boosted HDAC1 mRNA induction and enhanced IFNa-
mediated antiviral gene induction and anti-HCV activity. 
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Figure 15: Schematic representation of the role of HDACs in IFNa-
mediated anti-HCV gene expression in hepatocytes. 
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IMPAIRED SAM METABOLISM AND INTERFERON·ALPHA SIGNALING 
Impaired SAM metabolism decreases methylation potential in human 
hepatoma cells. 
SAM serves as the major methyl donor in transmethylation reactions and is 
converted to SAH after transfer of its methyl group. SAH, a potent inhibitor of 
methyltransferases, is rapidly broken down to homocysteine and adenosine by 
the enzyme SAHH, which is critical for removal of SAH and maintaining the 
SAM:SAH ratio (methylation potential). The reaction catalyzed by SAHH is 
reversible and the equilibrium favors the formation of SAH, but rapid cellular 
uptake of adenosine and homocysteine drives the reaction in the other direction6, 
14,47,80 (Fig. 2). We used the pharmacological SAHH inhibitors AD and DZA, as 
well as equimolar amounts of adenosine plus homocysteine (AdenHcy), to 
increase intracellular SAH and decrease methylation potential in human 
hepatoma cells. Cells were treated with these SAM metabolism disruptors for 3 
hours and deproteinized extracts were analyzed by HPLC. All the SAM 
metabolism disruptors induced an increase in intracellular SAH and this 
correlated to a decrease in SAM:SAH, or in methylation potential. These results 
clearly showed that AD, DZA, and AdenHcy are useful tools for decreasing 
methylation potential and supported the use of these SAM metabolism disruptors 
for studying the effects of impaired transmethylation on IFNa-mediated anti-HCV 
gene expression. 
43 
Impaired SAM metabolism blocks IFNa-inducible antiviral gene expression 
in human hepatoma cells. 
Decreased methylation potential, due to increased SAH and impaired SAM 
metabolism, has been documented in persons with chronic liver disease5, 6, 69. 
To determine how impaired SAM metabolism affects IFNa anti-HCV signaling, 
we used an Huh? cell line stably transfected with an HCV replicon (HCVR cells). 
Preliminary experiments revealed that 1 OU/mllFNa was sufficient to suppress 
HCV RNA induction by 50% after 24 hours of exposure. To analyze the effects 
of impaired SAM metabolism on the anti-HCV action of IFNa, HCVR cells were 
pretreated with SAM metabolism disruptors for 3 hours prior to stimulation with 
1 OU/mllFNa for 24 hours. Cells treated with IFNa alone showed a 50% 
suppression of HCV RNA, which was significantly reversed by pretreatment with 
SAM metabolism disruptors. AD partially reversed the action of IFNa, resulting in 
40% suppression of HCV, while AdenHcy and DZA completely blocked IFNa-
mediated anti-HCV activity. Importantly, DZA and AdenHcy treatment alone led 
to increased HCV RNA induction (Fig. 14). These data clearly show that 
impaired SAM metabolism, induced by either SAHH inhibition or exogenous 
AdenHcy supplementation, decreased the anti-HCV activity of IFNa. Importantly, 
DZA and AdenHcy alone led to an increase in HCV RNA replication, which 












Figure 16: Impaired SAM metabolism inhibits IFHa anti-HCV activity in 
human hepatoma cells. SAM metabolism disruptors (AdenHcy, AD, and DZA) 
significantly reversed IFNa-mediated suppression of HCV RNA. AdenHcyand 
DZA treatment alone enhanced HCV RNA induction. Error bars indicate SDM 
(N=3; a= PS 0.05 vs UT, b= PS 0.05 vs IFN). 
Next, we wanted to determine if the blockade of IFNa anti-HCV activity caused 
by SAM metabolism disruptors would correlate with reduced induction of IFNa-
stimulated antiviral genes PKR, OAS, and ISG15. IFNa led to marked induction 
of all the antiviral genes, which was significantly reduced by pretreatment with 
SAM metabolism disruptors. To confirm that these results were not an artifact of 
using a transfected cell line, we conducted the same experiments in the parental 
Huh? cell line. Similar to the results obtained in HCVR, pretreatment of Huh? 
cells with SAM metabolism disruptors inhibited IFNa-mediated induction of PKR, 
OAS, and ISG15 (Fig. 1?). Taken together, these results clearly demonstrate 
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Figure 17: Impaired SAM metabolism inhibits IFNa-mediated antiviral gene 
induction and anti-HCV activity in human hepatoma cells. SAM metabolism 
disruptors (AdenHcy, AD, and DZA) significantly reduced IFNa-mediated antiviral 
gene induction. Error bars indicate SDM (N=3; a= p~ 0.05 vs UT, b= p~ 0.05 
vs IFN). 
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Impaired SAM metabolism blocks IFNa-induced activation of the ISRE in 
antiviral gene promoters. 
Transcription of IFNa-stimulated antiviral genes is dependent on activation of the 
ISRE found in their promoters. Based on our data showing that SAM metabolism 
disruptors significantly inhibited IFNa-mediated antiviral gene induction and anti-
HCV activity, we hypothesized that impaired SAM metabolism may also block 
activation of the ISRE. Human hepatoma cells were transiently transfected in a 
large batch with an ISRE-Iuciferase reporter construct. Following transfection, 
cells were reseeded into 24-well plates and treated for 6 hours with IFNa alone, 
or stimulated with IFNa after 3 hour pretreatment with SAM metabolism 
disruptors. As expected, treatment with IFNa alone led to robust activation of the 
ISRE-Iuciferase reporter and pretreatment with SAM metabolism disruptors led to 
almost a complete attenuation of activation (Fig. 18). Previously data from our 
lab showed that treatment with AD inhibited binding of transcription factors to the 
ISRE in electrophoretic mobility shift assays. Taken together, these data support 
the idea that maintaining proper SAM metabolism is critical for activation of IFNa-
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Figure 18: Impaired SAM metabolism inhibits IFHa-mediated activation of 
the ISRE in human hepatoma cells. SAM metabolism disruptors (AdenHcy, 
AD, and DZA) blocked IFNa-stimulated ISRE activation in Huh 7 cells. SAM 
metabolism disruptors did not activate the ISRE. 
Impaired SAM metabolism inhibits IFHa-mediated pSTAT1, OAS, and PKR 
protein expression in human hepatoma cells. 
IFNa exerts its antiviral action by activating the JAKISTAT signaling cascade so it 
was important to determine if impaired SAM metabolism alters critical steps in 
the signaling pathway. IFNa binds cell surface receptors leading to activation of 
JAKISTAT signaling. Of particular importance in this cascade is phosphorylation 
of STAT proteins on tyrosine residue 701 (Y701), which causes them to dimerize 
and translocate to the nucleus where they associate with IRF9 to form the ISGF3 
transcription complex that binds the ISRE leading to antiviral gene induction. 
This pathway is regulated in several ways including dephosphorylation of STATs 
by phosphatases, and binding of STATs to their negative regulator protein 
48 
inhibitor of activated STATs (PIAS)73, 120. We performed western blots using 
whole cell Iysates from human hepatoma cells and analyzed the effects of DZA 
on IFNa-stimulated STAT1 Y701 phosphorylation. Cells treated with IFNa alone 
showed robust STAT1 Y701 phosphorylation, which was reduced in cells that 
received DZA prior to stimulation with IFNa (Fig. 19). To determine if DZA 
inhibits STAT1 Y701 phosphorylation by inducing phosphatases, we treated cells 
in the presence of sodium vanadate (Na3V04) and sodium flouride (NaF), which 
inhibit tyrosine and serine/threonine phosphatases, respectivell4. Interestingly, 
STAT1 Y701 phosphorylation was rescued with NaF but not Na3V04, thus 
suggesting that impaired SAM metabolism inhibits IFNa-mediated anti-HCV 
signaling by interfering with STAT1 serine phosphorylation. Several reports have 
indicated that phosphorylation of STAT1 on S727 is required for the optimal 
transcriptional activity of STAT1 106, 121, 127. To determine if STAT1 S727 
phosphorylation was affected, the membrane was stripped and reprobed with 
primary antibody against pSTAT1 S727. As seen in Figure 19, cells treated with 
DZA showed a marked decrease in pSTAT1 S727 when compared to cells 
treated with IFNa alone. To ensure that our results were not due to uneven 
loading of our protein samples, we also probed the blot with a total STAT1 
antibody. Total STAT1 was equal in all lanes confirming that DZA blocks IFNa-
mediated phosphorylation of STAT1 on both its Y701 and S727 residues. 
RT-PCR data revealed that impaired SAM metabolism downregulated IFNa-
stimulated antiviral gene induction. We treated human hepatoma cells for 24 
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hours with IFNa alone or after 3 hour pretreatment with DZA. Whole cell protein 
Iysates were collected and analyzed by Western blot for antiviral PKR and OAS 
protein expression . IFNa treatment induced expression of both PKR and ~AS. 
Pretreatment with DZA inhibited IFNa-stimulated OAS protein expression and 
slightly reduced PKR protein expression. j3-actin antibody was used to confirm 
equal loading between samples (Fig. 19). Taken together, these data show that 
impaired transmethylation affects IFNa-mediated anti-HCV action by disrupting 
critical steps in the JAKIST AT signaling cascade, which subsequently inhibits 
antiviral protein expression. 
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Figure 19: Impaired SAM metabolism inhibits IFNa-mediated pSTAT1, OAS, 
and PKR protein expression in human hepatoma cells. DZA inhibited IFNa-
mediated STAT1 phosphorylation and expression ofthe antiviral proteins, PKR 
and OAS, in whole cell protein Iysates from Huh 7 cells. Total STAT1 and f3-actin 
antibodies were used to confirm equal loading of proteins between samples. 
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Impaired SAM metabolism increases STA T1 :PIAS1, which correlates with 
decreased STA T1 :PRMT1 in the nucleus of human hepatoma cel/s. 
One mechanism by which JAKISTAT signaling is negatively regulated is through 
association of STAT1 with PIAS1 in the nucleus of cells. Importantly, formation 
of the STAT1 :PIAS1 complex is prevented by methylation of STAT1, which is 
catalyzed by association of STAT1 with the methyltransferase PRMT1 73, 85. 
Impaired SAM metabolism leads to an increase in intracellular SAH that inhibits 
methyltransferase reactions. To analyze the affects of impaired SAM metabolism 
on STAT1 :PIAS1, human hepatoma cells were treated with IFNa for 30 minutes 
alone or after 3 hour pretreatment with DZA or AD. Nuclear protein Iysates were 
collected and equal amounts of protein were immunoprecipitated with STAT1 
antibody. The immunocomplexes were analyzed by Western blot for association 
with PIAS1 and PRMT1. As seen in Figure 20, pretreatment with DZA or AD 
blocked IFNa-induced formation of STAT1 :PRMT1 complex, which correlated 
with an increase in STAT1 :PIAS1. These data support a role for SAM 
metabolism in regulation of IFNa-HCV signaling by controlling negative inhibition 














Figure 20: Impaired SAM metabolism decreases STA T1 :PRMT1 and 
increases STA T1 :PIAS1 association in the nucleus of human hepatoma 
cells. Immunoprecipitation of Huh 7 nuclear protein Iysates with STAT1 antibody 
revealed an IFNa-stimulated STAT1:PRMT1 complex that is inhibited by DZA 
(top). IFNa reduced STAT1:PIAS1 association, which was reversed by 
pretreatment with AD (bottom). 
SAM supplementation boosts IFNa-mediated antiviral gene induction and 
anti-HCV activity in human hepatoma cells. 
Our data clearly show that impaired SAM metabolism downregulates IFNa 
antiviral gene induction and anti-HCV activity and suggest that SAM plays a 
critical role in managing HCV by the current treatment regimen. Next, we wanted 
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to determine if SAM supplementation would enhance the anti-HCV actions of 
IFNa. HCVR cells were treated for 24 hours with 1 mM SAM prior to stimulation 
with 10U/mllFNa for 24 hours. Total RNA was extracted and used to analyze 
mRNA levels of PKR, OAS, and ISG15, as well as HCV RNA levels, by RT-PCR. 
IFNa treatment alone led to significant activation of the antiviral genes and SAM 
pretreatment caused at least a 2-fold enhancement of induction of each gene. 
Interestingly, SAM treatment alone cause significant induction of the antiviral 
genes. SAM pretreatment also enhanced the anti-HCV action of IFNa resulting 
in 75% suppression compared to 50% suppression seen in cells treated with 
IFNa alone. Importantly, SAM itself suppressed HCV RNA by 23% (Fig. 21). 
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Figure 21: SAM boosts IFHa-mediated antiviral gene induction and anti-
HCV activity in human hepatoma cells. SAM enhanced IFNa-mediated PKR, 
OAS, and ISG15 mRNA induction and suppression of HCV RNA. SAM treatment 
alone significantly induced antiviral mRNA induction and suppressed HCV. 
Error bars indicate SDM (N=3; a= p~ 0.05 vs UT, b= p~ 0.05 vs IFN). 
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Next, we wanted to determine if SAM supplementation would restore the anti-
HCV action of IFNa that was inhibited by SAM metabolism disruptors. HCVR 
cells were treated with DZA for 3 hours, then SAM for 24 hours, prior to 
stimulation with IFNa for 24 hours. HCV RNA was suppressed by 45% in cells 
that received IFNa and DZA blocked this effect, which brought HCV RNA levels 
back to baseline. Importantly, SAM supplementation restored the anti-HCV 
activity of IFNa, resulting in 49% suppression of HCV RNA (Fig. 22). Taken 
together, these data indicate a role for SAM supplementation, by enhancing IFNa 
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Figure 22: SAM restores IFNa-mediated anti-HCV activity that was blocked 
by inhibition of SAM metabolism. DZA reversed the anti-HCV action of IFNa 
in HCVR cells and this effect was blocked by SAM. Error bars indicate SDM 
(N=3; a= p~ 0.05 vs UT, b= p~ 0.05 vs IFN). 
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Impaired SAM metabolism downregulates HDAC gene induction in human 
hepatoma cel/s. 
Our previous studies using HDACi and siRNA demonstrated the critical need for 
HDAC1 and HDAC3 in IFNa-mediated anti-HCV activity. To expand on these 
findings, we wanted to determine if impaired SAM metabolism modified HDAC 
gene expression. Human hepatoma cells were treated with SAM metabolism 
disrupters for 3 hours then stimulated with IFNa for 2 hours. Total RNA was 
extracted and used to analyze induction of class I HDACs (1,2,3, and 8) and 
class II HDACs (4,5,6, 7a, 9, and 10) by RT-PCR. As seen in Figures 23 and 
24, none of the SAM metabolism disruptors induced significant changes in 
HDAC3 or HDAC5. HDAC1, HDAC6, and HDAC8 gene inductions were 
significantly reduced in cells that received AD. Cells treated with AdenHcy or 
DZA showed reduced induction of HDAC2 and HDAC9. Importantly, all of the 
SAM metabolism disruptors caused significant reduction in HDAC4, HDAC7, and 
HDAC10 gene induction (Fig. 24). These results support our previous data 
showing the requirement of HDACs in IFNa anti-HCV activity. The differential 
effects of the SAM metabolism disruptors on HDACs 1, 2, 6, 8, and 9 are 
possibly due to their specific chemical properties as opposed to being an effect of 
impaired SAM metabolism. Induction of HDACs 4,7, and 10 was suppressed by 
all SAM metabolism disruptors indicating these HDACs may playa critical role in 
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Figure 23: Effect of impaired SAM metabolism on class I HDAC gene 
induction in human hepatoma cells. Error bars indicate SOM (N=3; a= p~ 
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Figure 24: Effect of impaired SAM metabolism on class II HDAC gene 
induction in human hepatoma cells. Each of the SAM metabolism disruptors 
(AdenHcy, AD, and DZA) significantly reduced induction of HDAC4, HDAC7, and 
HDAC10 mRNA. Error bars indicate SDM (N=3; a= p~ 0.05 vs UT, b= p~ 0.05 
vs IFN). 
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Summary of data: 
.:. SAM metabolism disruptors blocked IFNa-mediated antiviral gene 
induction and suppression of HCV 
o AdenHcyand DZA boosted HCV RNA 
.:. SAM metabolism disruptors blocked IFNa-stimulated STAT1 
phosphorylation 
o Increased STAT1 :PIAS1 association 
o Decreased STAT1 :PRMT1 association 
.:. SAM metabolism disruptors inhibited HDAC4, HDAC7, and HDAC10 
mRNA induction 
.:. SAM supplementation boosted IFNa-mediated antiviral gene induction and 
suppression of HCV 
o SAM alone suppressed HCV RNA 
.:. SAM supplementation reversed the inhibitory action of DZA on the anti-
HCV action of IFNa 
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ACROLEIN AND INTERFERON-ALPHA SIGNALING 
Acrolein inhibits IFHa-mediated antiviral gene expression and anti-HCV 
activity in human hepatoma cells. 
HCV disease progression and response to IFNa therapy depend on a variety of 
factors including obesity, oxidative stress, and external factors such as smoking, 
and exposure to environmental pollutants35, 117, 122. Acrolein is a component of 
cigarette smoke, as well as an environmental pollutant, and can also be formed 
endogenously through the process of lipid peroxidation54, 56, 65, 90. We analyzed 
the effects of acrolein exposure on IFNa-mediated anti-HCV gene expression in 
human hepatoma cells. Cells were treated for 30 minutes with acrolein prior to 
stimulation with IFNa for 2 hours and total RNA was extracted and analyzed by 
RT-PCR. IFNa treatment caused robust induction of the antiviral genes PKR, 
OAS, and ISG15, which was significantly inhibited by pretreatment with acrolein 
(Fig. 25). Acrolein treatment alone significantly reduced PKR mRNA induction 
compared to UT cells. To determine if the reduction in antiviral gene 
transcription correlated with reduced anti-HCV activity of IFNa, HCVR cells were 
treated with acrolein for 30 minutes prior to stimulation with IFNa for 24 hours. 
IFNa alone suppressed HCV by 35% and pretreatment with acrolein dose-
dependently reversed the anti-HCV action. Interestingly, acrolein treatment 
alone significantly increased HCV RNA (Fig. 25). These data suggest that 
exposure to acrolein may contribute to HCV disease progression and poor 
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Figure 25: Acrolein inhibits IFNa-mediated antiviral gene expression and 
anti-HCV activity in human hepatoma cells. Acrolein dose-dependently 
inhibited IFNa-mediated antiviral mRNA induction and suppression of HCV RNA. 
Acrolein suppressed PKR mRNA and induced HCV RNA. Error bars indicate 
SDM (N=3; a= p~ 0.05 vs UT, b= p~ 0.05 vs IFN). 
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Acrolein suppresses class I HDAC activity and gene expression in human 
hepatoma cells. 
Based on our previous studies showing the critical role of class I HDACs in IFNa-
mediated anti-HCV signaling, we wanted to determine if acrolein modified HDAC 
activity and/or gene transcription. Nuclear protein Iysates were extracted from 
human hepatoma cells treated for 3 hours with increasing doses of acrolein. 
HDAC activity was measured using the Epigenase HDAC Activity Direct Assay 
Kit as per the manufacturer's protocol and normalized against protein 
concentration. HDAC activity was decreased in all samples and correlated with 
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Figure 26: Acrolein decreases HDAC activity in human hepatoma cells. 
Acrolein reduced HDAC activity in nuclear Iysates from Huh 7 cells. Data was 
normalized against protein concentration. Representative of 2 independent 
experiments. 
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In order to see if the decrease in HDAC activity correlated with reduced class I 
HDAC gene expression, human hepatoma cells were treated for 3 hours with 
acrolein and total RNA was extracted and analyzed by RT -PCR. As seen in 
Figure 27, acrolein significantly reduced transcription of all class I HDACs. 
Taken together, these results suggest that one mechanism by which acrolein 
inhibits IFNa anti-HCV activity is through inhibition of class I HDACs, which are 
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Figure 27: Acrolein decreases class I HDAC gene induction in human 
hepatoma cel/s. Acrolein significantly suppressed HDAC1, HDAC2, HDAC3, 
and HDAC8 mRNA induction in Huh? cells. Error bars indicate SDM (N=3; a= 
P$. 0.05 vs UT). 
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Summary of data: 
.:. Acrolein blocked IFNa-mediated antiviral gene induction and suppression 
ofHCV 
o Acrolein boosted HCV RNA 




HCV infection remains one of the leading causes of acute hepatitis and chronic 
liver disease in the US. Most people infected with HCV will develop chronic 
infections and approximately 50% of persons with HCV do not respond to the 
traditionallFNa plus ribavirin therapy. Poor response to therapy depends on a 
variety of factors including viral genotype, viral load, obesity, alcohol 
consumption, smoking, and exposure to environmental pollutants5, 35. 
Additionally, HCV invokes several countermeasures that inhibit the antiviral 
actions of IFNa including induction of PP2A, SOCS-1, SOC-3, and oxidative 
stress 11,52,69,104. Despite ongoing research on HCV, the molecular mechanisms, 
which include both host- and virus-specific factors, involved in resistance to 
therapy are not completely understood. These studies were performed to 
elucidate the mechanism(s) contributing to resistance to therapy and poor 
treatment outcomes in the management of HCV. 
HDACs were historically identified based on their ability to remove acetyl groups 
from K residues on histone tails. The removal of these acetyl groups removes 
the negative charges that repel DNA, leading to chromatin condensation and 
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reduced transcription due to inaccessibility of transcription machinery to gene 
promoters. In more recent years, there has been a growing body of evidence 
showing that HDACs also exert action on non-histone proteins, in particular 
transcription factors, leading to altered gene expression41 , 87, 124. The possible 
role of HDACs in modifying gene expression due to transcription factor 
modifications must be considered in inducible gene systems. 
Taking into account the historical role of HDACs in downregulating gene 
expression due to chromatin condensation, we expected to see enhanced 
antiviral gene expression and suppression of HCV RNA when human hepatoma 
cells were treated with HDAC inhibitors prior to stimulation with IFNa. We 
instead observed a decrease in antiviral gene expression, which correlated with 
inactivation of the ISRE, and partial reversal of the anti-HCV action of IFNa. The 
anti-HCV properties of IFNa are mediated through activation of the JAKISTAT 
signaling cascade. Critical steps in this pathway include phosphorylation of 
STAT1 on Y701 and S727, which are required for nuclear translocation and 
optimal transcriptional activity, respectivell8, 100, 121, 127. We initially performed 
Western blot analysis on whole cell protein Iysates from appropriately treated 
cells but did not observe a change in STAT1 phosphorylation in cells that 
received HDACi prior to stimulation with IFNa. However, when we analyzed 
STAT1 phosphorylation in cytoplasmic and nuclear protein Iysates, we noticed a 
clear difference in the partitioning of pSTAT1; HDACi pretreated cells showed 
cytoplasmic accumulation compared to nuclear accumulation in cells stimulated 
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only with IFNa. STAT signaling can be inhibited by acetylation of STAT1 in the 
nucleus, which leads to its translocation out of the nucleus and reduced gene 
transcription. Acetylation of STAT1 in the nucleus is mediated through binding 
with the HAT protein CBp58, 61, 62. Our data showed that IFNa induced formation 
of a STAT1 :HDAC1 complex in the nucleus and HDACi pretreatment inhibited 
formation of this complex, which correlated to an increase in STAT1 acetylation. 
It is reasonable to speculate that, in addition to recruiting RNA polymerase to 
antiviral gene promoters, HDACs playa critical role in regulating IFNa-mediated 
anti-HCV gene expression by aSSOCiating with STAT1 to circumvent CBP-
induced acetylation and retain activated STATs in the nucleus. 
The HDAC inhibitors used in our experiments, TSA and SBHA, are class I HDAC 
inhibitors and decrease the activity of HDACs 1, 2, 3, and 8. Using siRNA, we 
identified HDACs 1 and 3 as being critical for IFNa-mediated anti-HCV gene 
expression. Silencing of HDAC1 or HDAC3 led to a partial, yet significant, 
decrease in IFNa-stimulated anti-HCV gene expression and also inhibited 
formation of the STAT1 :HDAC1 complex. Taken together, these results suggest: 
1) there is redundancy between the HDACs that allows one to compensate when 
the other is silenced; and 2) HDAC3 plays a role in keeping STATs deacetylated 
and retained in the nucleus. The role of HDAC3 in keeping STATs deacetylated 
is supported by other data from our lab showing formation of a STAT2:HDAC3 
complex in nuclear Iysates from IFNa stimulated cells. Additionally, we observed 
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HDACi-induced retention of pSTAT2 in cytoplasmic Iysates of IFNa-stimulated 
cells. 
When compared to pretreatment with HDACi, silencing of HDAC1 or HDAC3 by 
siRNA suppressed IFNa-mediated antiviral gene induction to a much lesser 
degree. The differences between the results obtained with HDACi versus siRNA 
are likely due to the fact that TSA and SBHA block activity of all class I HDACs, 
whereas siRNA blocks induction and expression of the respective HDAC genes. 
It is reasonable to speculate that double transfection with both siHDAC1 and 
siHDAC3 may reduce IFNa-stimulated antiviral gene induction to levels similar to 
those obtained with HDACi pretreatment. Alternatively, there may be 
redundancy between the HDACs that causes one to be induced when the other 
is silenced. Further studies are needed to further elucidate the roles of HDAC1 
and HDAC3 in IFNa-mediated anti-HCV gene expression. 
Recent reports have shown that theophylline induces HDAC activity to modify 
gene expression22, 53. To further elucidate the role of HDACs in IFNa-mediated 
anti-HCV signaling, we used theophylline to boost HDAC gene expression and 
analyzed its effects on antiviral gene induction. We observed a theophylline-
induced increase in HDAC1 mRNA induction, which correlated with enhanced 
IFNa-mediated PKR mRNA induction and suppression of HCV RNA. 
Importantly, theophylline alone induced PKR mRNA and suppressed HCV RNA 
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induction. These data are consistent with a recently published report showing 
that theophylline inhibits replication of hepatitis B virus 128. 
The theophylline doses used in this study were used for proof-of-concept and are 
not physiologically relevant. However, theophylline is known to boost HDAC 
activity and is a metabolite of caffeine. Freedman et al have reported that HCV 
patients who consume coffee have better response to the IFNa plus ribavirin 
therapy. It is possible that the enhanced antiviral response is partially due to the 
caffeine found in coffee. 
SAM is of pivotal importance in cellular metabolism serving as the major donor of 
methyl groups in transmethylation and transsulfuration reactions. Elevations in 
intracellular SAH will disrupt the SAM metabolism pathway and impaired SAM 
metabolism is a well documented feature of chronic liver injurl' 75, 77. Our data 
clearly show that disrupting SAM metabolism, by SAHH inhibition or exogenous 
supplementation of adenosine and homocysteine, dramatically reduced IFNa-
stimulated antiviral gene induction, which correlated with impaired activation of 
the ISRE, and reversed the anti-HCV action of IFNa. Western blot analysis 
revealed a decrease in both pSTAT1 Y701 and pSTAT1 S727 in whole cell protein 
Iysates from cells treated with SAM metabolism disruptors prior to stimulation 
with IFNa. Negative regulation of JAKISTAT signaling occurs when STAT1 is 
bound to PIAS1, an association that is controlled by PRMT1-induced methylation 
of STAT1. Immunoprecipitation of nuclear Iysates with STAT1 antibody revealed 
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IFNa-induced formation of a STAT1 :PRMT1 complex that was inhibited by 
pretreatment with SAM metabolism disruptors. Importantly, SAM metabolism 
disruptors caused an increase in the STAT1 :PIAS1 complex compared to cells 
treated with IFNa alone. Previous data from our lab also revealed methylation of 
STAT1 that was inhibited by treatment with SAM metabolism disruptors These 
data suggest a critical role for SAM metabolism in IFNa-mediated anti-HCV gene 
expression. 
Exogenous supplementation of SAM significantly enhanced in IFNa-mediated 
anti-HCV gene expression and suppression of HCV RNA. Importantly, SAM 
treatment alone significantly induced PKR, OAS, and ISG15 mRNA induction and 
suppressed HCV RNA. Previous data from our lab also revealed that SAM 
supplementation increased methylation of STAT1 , which correlated with a 
decrease in STAT1 :PIAS1. Finally, SAM supplementation reversed the inhibitory 
effects of DZA on IFNa-mediated antiviral gene expression and anti-HCV activity. 
These data suggest a role for SAM as adjunct therapy in management of HCV. 
A recently published report by Feld et a/ indeed showed that SAM improved early 
response in HCV patients on IFNa plus ribavirin therapy who previously did not 
respond to the traditional anti-HCV therapl1. Additionally, our data showing 
suppression of HCV by SAM treatment alone suggests that the HCV promoter 
might be controlled by methylation and points to the need for future studies in this 
area. 
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HDACs are required for IFNa-mediated antiviral gene expression and we 
specifically identified HDAC1 and HDAC3 as being critical for IFNa anti-HCV 
activity. Interestingly, none of the SAM metabolism disruptors affected induction 
of HDAC1 or HDAC3. Next, we analyzed the effects of these disruptors on class 
II HDAC inductions. HDAC4, HDAC7, and HDAC10 were significantly 
downregulated in response to each SAM metabolism disruptor used in this study 
suggesting that these HDACs play an important role in IFNa antiviral signaling as 
well as SAM metabolism and maintaining the SAM/SAH ratio. Future studies 
are needed to determine if these HDACs playa role in regulating STATs and/or 
other transcription factors required for IFNa-mediated anti-HCV gene expression. 
Additionally, these HDACs may modify the epigenetic landscape, including 
alterations in chromatin structure, at IFNa antiviral gene promoters. Finally, it is 
possible that HDACs 4,7, and 10 affect enzymes in the SAM metabolism 
pathway, such as MAT1 or SAHH enzymes, thus regulating SAM formation 
and/or utilization. 
Acrolein is a hepatotoxic aldehyde that is a component of smoke, as well as a 
product and inducer of oxidative stress, and exposure to acrolein might correlate 
to poor response to IFNa anti-HCV therapl4. In fact, smokers have a lower 
response to IFNa anti-HCV therapy than nonsmokers, which correlates with an 
increase in liver fibrosis29. We used sublethal doses of acrolein, which were also 
within the physiological range, to show that acrolein downregulated IFNa-
mediated antiviral gene expression and reversed the anti-HCV action of IFNa. 
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Importantly, acrolein alone led to an increase in HCV RNA suggesting that 
exposure to acrolein enhances disease progression and contributes to poor 
response to therapy. Acrolein also significantly reduced HDAC activity and 
induction of the class I HDACs: HDAC1, HDAC2, HDAC3, and HDAC8. Previous 
data from our lab also showed that acrolein impairs IFNa-induced JAKISTAT 
signaling by inhibiting phosphorylation of STAT1 and STAT2, which correlated to 
an increase in serine and tyrosine phosphatase activitl4. These data clearly 
show a role for acrolein in reducing IFNa-mediated antiviral gene expression and 




The data presented herein show that HDACs and SAM play critical roles in 
regulating IFNa antiviral signaling and anti-HCV activity. We have presented 
convincing evidence that HDACs modify signaling by keeping the transcription 
factor STAT1 deacetylated, which increases its retention in the nucleus. We also 
show that HDACs are required for STAT binding to antiviral gene promoters, 
however, it is reasonable to assume that HDACs also modify local chromatin 
structure at IFNa-stimulated anti-HCV gene promoters to alter gene transcription. 
The critical role of HDACs in IFNa anti-HCV signaling is further supported by the 
fact that SAM metabolism disruptors and acrolein all modified the activity and/or 
induction of several HDACs. 
SAM metabolism is required for IFNa-mediated anti-HCV gene expression and to 
prevent association between STAT1 and its negative regulator PIAS1. SAM 
metabolism disruptors significantly reduced induction of HDAC4, HDAC7, and 
HDAC10 mRNAs. These HDACs may play critical roles in maintaining SAM 
metabolism and SAM/SAH ratio in hepatocytes. Alternatively, these HDACs may 
modify other transcription factors in the IFNa anti-HCV signaling pathway. 
Finally, SAM treatment alone suppressed HCV RNA suggesting that the HCV 
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genome may be under methylation control and points to the need for future 
studies. 
Acrolein exposure significantly reduced IFNa-mediated antiviral gene induction 
and anti-HCV activity. Acrolein suppressed the activity and induction of all class I 
HDACs: HDAC1, HDAC2, HDAC3, and HDAC8. Importantly, acrolein treatment 
itself induced HCV RNA induction. Acrolein induces oxidative stress, which 
correlates with HCV disease progression and poor treatment outcomes, 
however, it is possible that acrolein-induced inhibition of HDAC activity and/or 
expression also contributes to poor IFNa anti-HCV response. 
Overall conclusion: 
We have elucidated the critical roles of HDACs and SAM in IFNa signaling and 
epigenetic regulation of anti-HCV gene expression. SAM and/or HDAC inducers 
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